Embryonic skeletal joint development

pathway activity — cross-omics
GO:0072498Cross-omicsPROTEIN-MS → DRUGCellPairwise association · TCGA cohorts

Across TCGA cell cohorts, RNA activity of the Embryonic skeletal joint development pathway is significantly associated with the drug response of multiple features, with the BREAST cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Etoposide, JNK-9L, and POMHEX, each associated with the pathway in up to 1 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Etoposide grouped by Embryonic skeletal joint development-low versus -high activity in BREAST.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.
LineagePartner featureX-scoreY-scorep(X)p(Y)Sampling consensusLineage consensus
BREASTEtoposide →+1.493+0.177.018.03821
BREASTJNK-9L →+0.333+0.177.001.03821
BREASTPOMHEX →+0.408+0.177.002.03821
BREASTARRY-520 →+2.105+0.177.006.03821
BONEOSI-027 →+0.990+0.169.019.03221
BREASTVinblastine →+1.258+0.177.028.03811
Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Etoposide by Embryonic skeletal joint development activity — BREAST

Box plot of Etoposide in Embryonic skeletal joint development-low vs -high samples in BREAST.

Explore this box plot interactively →

Exploration